Kornimate/medical-research-clean huggingface dataset:
human papillomavirus in young people epidemiological research 2 (hyper2)

Conditions: Human Papillomavirus; Human Papillomavirus Infection

Summary: australia was one of the countries to implement a universal school-based male vaccination program - in 2013. this research project will examine the prevalence of hpv among young men who have sex with men (msm) who have been offered school-based hpv vaccination.

hyper-2, will be a cross-section study, using the same recruitment and testing strategies used in hyper 1, which determined the prevalence of anal, genital and oral hpv among men who have sex with men aged 16-20 years. given the differing age groups that will have been offered vaccination over the 2 study period, men aged 16-19 will be recruited in the first year (2017) and men aged 16-20 will be recruited in the second year (2018) to ensure that the participants included in the hyper-2 study would have been eligible for the free male hpv vaccine in australia. a total of 200 men will be recruited over a 2-year period, and hpv vaccination status for each participant will be verified against the national hpv vaccination program register. this 2-year cross-sectional study will recruit men who report sex with men aged from 16 to 20 years.

Eligibility criteria:
inclusion criteria: * men aged 16 to 20 (must be aged 16-19 years from 1 january 2017 to 31 december 2017, and aged 16-20 years from 1 january 2018 to 31 december 2018) * report any previous type of sexual contact (including but not restricted to oral or anal sex) with at least one other man ever * able to complete all study requirements including questionnaire in english and completion of 2 visits * residing in australia since 2013 (this is to ensure that males included in the study were present in australia at the time hpv vaccination was offered) exclusion criteria: * transgender male
a pediatric safety and pharmacokinetics study of ha44 gel administered topically for treatment of head lice infestation

Conditions: Head Lice Infestation

Summary: the primary purpose of the study is to evaluate safety and tolerability of a single application of ha44 gel 0.74% w/w for the treatment of head lice. secondary purpose is to evaluate pk of ha44 and benzyl alcohol under conditions of maximal exposure in pediatric population.


Eligibility criteria:
inclusion criteria: 1. male or female, 6months \< 3years of age 2. good health 3. active head lice infestation defined as the presence of at least 3 live lice 4. dermatological condition of scalp (at least g2 erythema or pruritus with evidence of excoriation/inflammation) 5. parent/guardian agrees to allow pk samples collected 6. signed informed consent form exclusion criteria: 1. condition or illness that in the opinion of the investigator may interfere with the study results. 2. current dermatological disease that may compromise the health of subject or the assessment of safety. subjects with scalp ulceration or evidence of scalp infection should not be enrolled. 3. prior reaction to product containing piperonyl butoxide, pyrethrin, or pyrethrum extract. 4. receiving systemic or topical medication that may interfere the study results. 5. received an investigational agent within 30 days prior to day 0.
effects of mscs derived pleiotropic factors on wound healing in endonasal surgeries

Conditions: MSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries

Summary: nasal trauma, deviated nasal septum, sinusitis, nasal polyps and other nasal benign diseases are common clinical diseases and require endoscopic sinus surgery. the proper application of the surgical procedure as well as ensuring high quality of wound healing, is also important to achieve successful results in endoscopic sinus surgery. if good quality wound healing cannot be achieved in the surgical field,synechiae and anatomic defects can occur that may require revision surgeries. mesenchymal stem cells play an active role in the treatment of many diseases. it primarily exerts therapeutic effects through paracrine. in this study, the effect of mesenchymal stem cell-derived multipotent factors on mucosal repair after nasal surgery was evaluated.


Eligibility criteria:
inclusion criteria: 1. 18 to 60 years old; 2. the clinical diagnosis is nasal trauma, nasal septum deviation, sinusitis, and nasal polyps requiring endoscopic surgery; 3. the patient's physical and mental state is stable, and he can return to the hospital regularly for follow-up examinations and cooperate to complete the experiment; exclusion criteria: 1. younger than 18 or older than 60; 2. clinical diagnosis of nasal malignancies, or uncontrolled severe infectious diseases; 3. past medical history of mental illness, malignant tumor, nose surgery; 4. people with serious underlying diseases (hypertension, diabetes, rheumatism, asthma) require long-term medication; 5. long-term smoking, more than 5 cigarettes per day; 6. work or daily life environment is exposed to large amounts of dust and chemical raw materials;
effect of spirulina on periodontitis

Conditions: Periodontitis

Summary: the purpose of this study is to assess the clinical and immunological effect of spirulina in treatment of stage ii periodontitis.

in this study, the investigators tested the effect of spirulina gel as adjunctive of scaling and root planing in treatment of stage ii, grade b periodontitis in term of probing pocket depth reduction, mean gain in clinical attachment level, and level of interleukin 6.

Eligibility criteria:
inclusion criteria: * all the patients suffer from stage ii, grade b periodonitis with attachment loss 3-4 mm and probing pocket depth ≤ 5mm. exclusion criteria: * any systemic disease that affects the periodontium. · * pregnant, postmenopausal women. · * people who take anti-inflammatory drugs, antibiotics, or vitamins within the previous 3 month. * people who use mouth washes regularly · * participation in other clinical trials.
gluten free diet in ibs patients stratified according to their antigliadin status

Conditions: IBS - Irritable Bowel Syndrome

Summary: gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of irritable bowel syndrome (rome iii criteria). antibodies to native gliadin (aga) have been suggested as a potential diagnostic marker of response to gfd. however, this has not been tested in a prospective study in ibs patients. identification of predictors of a symptomatic response to gfd within the ibs population would improve the clinical management of these patients. the purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with irritable bowel syndrome stratified according to their antigliadin antibodies status. additional purposes include investigating effects gluten free diet may have on other parameters: * improvement of mood * quality of life and general well-being * changes in gut microbiota


Eligibility criteria:
inclusion criteria: * adult patients * ibs diagnosis (rome iii) * willingness to participate exclusion criteria: * history of any organic disease including celiac disease * immune deficiency * major abdominal surgery * use of immunosuppressants, glucocorticosteroids or opioids * use of antibiotics in the last 3 months

Keywords: antigliadin, gluten free diet, transit
high threshold peanut challenge study

Conditions: Peanut Allergy

Summary: this protocol is designed to better characterize a sub-population of peanut sensitized individuals who may be non-allergic, despite significant sensitization, or who may be allergic, but at high threshold doses. by specifically targeting participants who met the initial screening criteria of the active adult pn oit study, protocol 2012p002153 / aadcrc mgh-004 (mgh-004), but failed to react during the pre-treatment 443 mg challenge to peanut, the investigators anticipate that the investigators will identify individuals who have become spontaneously tolerant, despite persistent sensitization. the investigators might also find that clinical sensitivity persists but only with higher thresholds, or that sensitivity has increased (or is variable) since the previous allergen exposure. by repeating dbpcfcs through to a full serving dose (7.4 gram), the investigators will distinguish participants who react only at higher doses from those who were not truly peanut allergic, address whether their sensitivity has changed, and have the opportunity to further investigate their immune response to peanut allergen.

the primary objective of the study is to identify and characterize a sub-population of high-threshold peanut allergic individuals and characterize their immunological phenotype in comparison with the low-threshold peanut allergic individuals enrolled in the adult pn oit study (nct01750879). clinical objective: to evaluate the clinical status of peanut-sensitized individuals previously passing a dbpcfc to 443 mg as being either: non-allergic, stably high-threshold allergic or more clinically reactive on repeat exposure.

Eligibility criteria:
inclusion criteria: * failure to react to 443 mg of peanut protein during the dbpcfc1 visit of protocol 2012p002153 / aadcrc mgh-004. * males and females of all ethnic/racial groups aged 7-55 years old who are otherwise healthy. * willingness to sign consent (or for parent/guardian to sign consent). * willingness to sign the assent form, if consent provided by parent/guardian. exclusion criteria: * history of severe anaphylaxis * severe or moderate asthma * poorly controlled asthma * diagnosis of other severe or complicating medical problems, including autoimmune or chronic immune inflammatory conditions or gastrointestinal inflammatory conditions * inability to cooperate with and/or perform oral food challenge procedures * primary immune deficiency * current use of beta blockers, angiotensin converting enzyme inhibitors, or monoamine oxidase inhibitors * women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding * use within the past 6 months of other systemic immunomodulatory treatments * clinical signs or symptoms of anemia * hematocrit \<0.36 for adult females or \<0.38 for adult males * hematocrit \<0.34 for children 7-18 years of age * weight \<23 kg

Keywords: food allergy peanut food challenge
comparative effectiveness of akynzeo® and standard of care (including emend®) for the prevention of nausea and vomiting (cinv) in cancer patients

Conditions: Oncology

Summary: this pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between akynzeo® and standard of care (soc, including emend®) in the real-life setting


Eligibility criteria:
inclusion criteria: * male or female, age ≥ 18 years * have a histological or cytological confirmed solid tumor malignancy * patient scheduled to receive their first course of anthracycline cyclophosphamide (ac) based chemotherapy regimen or moderately emetogenic chemotherapy for the treatment of solid malignant tumor * patient scheduled to receive cinv prevention with akynzeo® or standard of care according to the summary of product characteristics based on the judgement of their investigator's * naïve of ct * ecog performance up to 2 * able to read, understand and follow the study procedures * patient with health insurance exclusion criteria: * pregnancy and breastfeeding women; * hypersensitivity to active substances, excipients or other ingredients of akynzeo® or emend®; * protected patients: majors under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
radical cystectomy: can we improve our surgical technique with the ligasure impact tissue-sealing device?

Conditions: Bladder Cancer; Hemostasis

Summary: evaluate the utility/safety of an fda-approved tissue sealing device during radical cystectomy as compared to an fda-approved stapling device.


Eligibility criteria:
inclusion criteria: * muscle invasive bladder cancer * male/female gender exclusion criteria:

Keywords: tissue sealing device articulating stapling device radical cystectomy
approach 2.0: hiv, hcv and syphilis testing through pharmacies

Conditions: HIV Infections; HCV Infection; Syphilis Infection

Summary: human immunodeficiency virus (hiv), hepatitis c (hcv), and syphilis are sexually transmitted and blood borne infections (stbbi) that affect millions of people worldwide and rates are rising in canada. hcv and syphilis are curable, and hiv is treatable with virtually no risk of transmission to sexual partners when the infection is controlled, however, these outcomes require adequate testing. unfortunately, an estimated 44% of canadians living with hcv and 13% living with hiv are not diagnosed. these undiagnosed cases are the source of over half of new hiv infections. furthermore, hiv-syphilis coinfection is common. accessible testing forms a key pillar of an elimination strategy and acts as an access point for linking people to care. community pharmacies are more accessible site for stbbi testing, compared to hospitals and doctors' offices. this is especially true for members of marginalized communities, some of whom are at higher risk of infection. the covid-19 pandemic highlighted the need for low-barrier stbbi testing, as in-person healthcare services at doctors' offices and traditional screening clinics were scaled back. pharmacies remained open throughout the pandemic. the approach 2.0 study will assess the impact of a pharmacy-based testing program for hiv, hepatitis c, and syphilis in participating pharmacies in three canadian provinces: newfoundland \& labrador, alberta, and nova scotia on finding new diagnoses and linkages with care. participants will be offered point of care tests for hiv and/or hcv and/or a dry blood spot test which will test for hiv, hcv, and syphilis. these tests are easy to administer. results from the point of care tests are available immediately during the pharmacy visit while participants will be contacted with dried blood spot test results when available (approximately 2 weeks). participants with reactive tests are linked with confirmatory testing and care, and those with non-reactive results are offered preventative services including hiv prep (as indicated) and counselling. this study builds on a pilot study completed in 2017 (www.approachstudy.ca).


Eligibility criteria:
inclusion criteria: * ages 18 years and older, speaks english, has provincial health card number, and is able and willing to provide informed consent. exclusion criteria: * unwilling or unable to provide informed consent. participants who have been previously diagnosed with hiv infection will not be eligible for hiv testing (point of care test or dry blood spot test). participants who have previously been diagnosed with hcv are not eligible for hcv point of care test, but may request a dry blood spot test.
cryotherapy versus radiofrequency catheter ablation research program

Conditions: Atrial Fibrillation; Atrial Tachycardia; Wpw; Ventricular Tachycardia

Summary: a program of research has been set up at st. george's hospital, london studyng the practicalities of catheter ablation. the current practice of catheter ablation is being studied for a range of arrhythmias including paf, persistent af, advanced persistent af and resistant wpw.

the study design will be a separate randomised clinical trial for each of the arrhythmias studied. there will be 1:1 randomisation to either the cryotherapy protocol or rf protocol. arrhythmia patients already under the care of this cardiac centre, who have already opted for catheter ablation treatment will be approached to ask if they will also be willing to participate in this longterm research program. the protocols for each different arrhythmia are in line with current practice and knowledge and utilising current technology. in the program, the investigators have 1 or 2 protocols that mildly differ from conventional use but have already passed through initial experience with publication on this- this is the multi-catheter cryocatheter approach. acute procedural outcomes, short, medium and longterm success will be recorded for each patient, in addition to patient or participant experience and quality of life outcomes. the catheter ablation research program has passed through ethical panel review in london and has the potential to become a multi-centre study.

Eligibility criteria:
inclusion criteria: * adult patients under the care of the arrhythmia service at st. george's hospital with one of the studied arrhythmia (paf, persistent af etc), awaiting catheter ablation treatment will be eligible for inclusion to the program of research exclusion criteria: * vulnerable patients will be excluded- e.g. active cancer, inability to consent * paediatric patients will not be studied * patients awaiting standard svt catheter ablation treatment

Keywords: catheter ablation techniques
characterization of aerosol generation and transport in the human lung of subjects with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study is aiming at evaluating the characteristics of particle emission in subjects with different stages of chronic obstructive pulmonary disease (copd) compared with healthy smokers.


Eligibility criteria:
inclusion criteria: 1. male or female subjects, aged ≥ 18 years 2. copd: physician diagnosis of chronic obstructive pulmonary disease (copd gold i to iv according to gold guidelines)9 3. healthy smokers: current smokers with a history of at least 10 packyears and no signs of bronchial obstruction in spirometry (fev1 \>= 80% pred, fev1/fvc \>= 70%) 4. able and willing to give written informed consent 5. women will be considered for inclusion if they are: * not pregnant, as confirmed by pregnancy test, and not nursing * of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit) * of childbearing potential and using a highly effective method of contraception during the entire study (vasectomized partner, sexual abstinence) - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study , implants, injectables, combined oral contraceptives, hormonal iuds, or double-barrier methods, i.e. any double combination of iud, condom with spermicidal gel, diaphragm, sponge, and cervical cap) 6. available to complete all study measurements exclusion criteria: 1. history of lower respiratory tract infection four weeks prior to the informed consent visit 2. past or present disease, which as judged by the investigator, may affect the outcome of this study. these diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to tuberculosis, bronchiectasis or cystic fibrosis) 3. history of drug or alcohol abuse 4. suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study 5. inability to abstain from bronchodilators according to section 8.2 (prohibited medication) 6. risk of non-compliance with study procedures

Keywords: copd
pelvic exenteration in treating patients with recurrent cervical cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma

Summary: this phase ii trial is studying how well pelvic exenteration works in treating patients with recurrent cervical cancer. pelvic exenteration may be effective in treating recurrent cervical cancer.

primary objective: i. correlate progression-free survival and overall survival with tumor size, time interval between primary cancer management and pelvic exenteration, and presence or absence of pelvic sidewall fixation by clinical examination in patients with recurrent cervical cancer treated with pelvic exenteration. secondary objectives: i. determine quality of life of patients treated with this procedure. ii. correlate quality of life with reconstructive technique (e.g., no ostomy or ≥ 1 ostomy) in patients treated with this procedure. outline: patients undergo pelvic exenteration within 14 days after study entry. quality of life is assessed at baseline and at 6, 12, and 24 months after surgery. after completion of study treatment, patients are followed within 30 days, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * diagnosis of cervical cancer * any histology * documented or suspected central pelvic disease with or without pelvic sidewall fixation from tumor and/or radiation fibrosis * meets 1 of the following stage criteria: * recurrent disease, defined as reappearance of disease after a complete clinical response lasting ≥ 1 month * persistent disease, defined as presence of disease by biopsy ≥ 3 months after completion of primary therapy * must have received prior primary treatment, including any of the following: * surgery with or without post operative radiotherapy with or without chemotherapy * primary radiotherapy with or without chemotherapy * neoadjuvant chemotherapy followed by surgery * neoadjuvant chemotherapy followed by surgery with or without radiotherapy or chemotherapy * plans to undergo pelvic exenteration to remove the pelvic disease within 14 days after study entry * deemed to be a good surgical candidate * no evidence of distant disease or disease that is felt to be unresectable by physical examination * patients with suspicious pelvic or para-aortic nodal disease as the only site(s) of extrapelvic disease are eligible at the discretion of the surgeon * patients whose surgery is planned solely for managing complications (e.g., rectovaginal fistula, vesicovaginal fistula) of disease or prior therapy are not eligible * patients whose surgery is planned as a prophylactic measure due to a slow or suboptimal clinical or radiographical tumor response during the course of primary therapy are not eligible * no distant site of metastases by ct scan or mri of the abdomen/pelvis or positron-emission tomography * no noncervical primary tumor * no prior anterior or posterior pelvic exenteration
ointment to prevent scar after thyroidectomy

Conditions: Scar

Summary: the goal of this study is to evaluate the efficacy and safety of inv-001 administration for the prevention of scar after thyroidectomy. participants will be asked to apply ointment on their scar for 12 weeks.

to evaluate the efficacy -investigator check posas and vss

Eligibility criteria:
inclusion criteria: * patient who got thyroidectomy due to thyroid cancer * has scar longer than 3 cm exclusion criteria: * have history about keloid or hypertrophic scar * have infection on surgical site